Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
P/E ratio for Hanmi Science Co., Ltd. (008930.KS)
P/E ratio as of 2023: 23.14
According to Hanmi Science Co., Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.14. At the end of 2022 the company had a P/E ratio of 31.32.
P/E ratio history for Hanmi Science Co., Ltd. from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 23.14 |
| 2022 | 31.32 |
| 2021 | 84.91 |
| 2020 | 222.12 |
| 2019 | 79.11 |
| 2018 | 269.14 |
| 2017 | 229.38 |
| 2016 | 404.77 |
| 2015 | 40.71 |
| 2014 | 40.87 |
| 2013 | 73.12 |
| 2012 | 31.78 |
| 2011 | -13.23 |
| 2010 | 44.11 |
| 2009 | 5.21 |
| 2008 | 1.85 |
| 2007 | 5.38 |